149 related articles for article (PubMed ID: 19330772)
1. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis.
Van Meter DJ; Corriveau M; Ahern JW; Lahiri T
Pediatr Pulmonol; 2009 Apr; 44(4):325-9. PubMed ID: 19330772
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
[TBL] [Abstract][Full Text] [Related]
3. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
4. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
[TBL] [Abstract][Full Text] [Related]
5. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
[TBL] [Abstract][Full Text] [Related]
7. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Madsen V; Lind A; Rasmussen M; Coulthard K
J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
[TBL] [Abstract][Full Text] [Related]
8. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
Massie J; Cranswick N
J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
[TBL] [Abstract][Full Text] [Related]
10. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
Prescott WA
Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
[TBL] [Abstract][Full Text] [Related]
11. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
Vandenbussche HL; Klepser ME
Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
[No Abstract] [Full Text] [Related]
12. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
[TBL] [Abstract][Full Text] [Related]
13. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
14. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Tré-Hardy M; Traore H; El Manssouri N; Vanderbist F; Vaneechoutte M; Devleeschouwer MJ
Int J Antimicrob Agents; 2009 Oct; 34(4):370-4. PubMed ID: 19505804
[TBL] [Abstract][Full Text] [Related]
16. Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.
Scheenstra RJ; Rijntjes E; Tavy DL; Kingma H; Heijerman HG
Acta Otolaryngol; 2009 Jan; 129(1):4-7. PubMed ID: 18607923
[TBL] [Abstract][Full Text] [Related]
17. Tobramycin dosing in cystic fibrosis.
Smyth A; Touw D; Tan KH; Bertenshaw C; Stableforth D
Lancet; 2005 May 21-27; 365(9473):1767-8. PubMed ID: 15910946
[No Abstract] [Full Text] [Related]
18. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
Bartel K; Habash T; Lugauer S; Bärmeier H; Böwing B; Unsal M; Schoerner C; Heininger U
Infection; 1999; 27(4-5):268-71. PubMed ID: 10885841
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM
J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
[TBL] [Abstract][Full Text] [Related]
20. [Anti-Pseudomonas aerosol therapy in cystic fibrosis: improvement with tobramycin].
Foucaud P; Borel B; Charara O; Nathanson S; Petitprez P; Pin I
Rev Pneumol Clin; 2002 Jun; 58(3 Pt 1):131-8. PubMed ID: 12486796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
